Mackenzie Financial
ACRS icon

Mackenzie Financial’s Aclaris Therapeutics ACRS Stock Holding History

Mackenzie Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-213,405
Closed -$800K – 1557
2026
Q1 		$800K Buy
+213,405
New +$720K ﹤0.01% 1121

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Mackenzie Financial's ACRS Position: Q2 2026 in Review

Mackenzie Financial sold out of Aclaris Therapeutics (ACRS) in Q2 2026, closing a stake of 213,405 shares — an estimated $800K sold.

Mackenzie Financial first reported a position in ACRS in Q1 2026 and held it in 1 quarter. The position peaked at $800K in Q1 2026. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Mackenzie Financial reported no remaining Aclaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mackenzie Financial sold 213,405 Aclaris Therapeutics shares in Q2 2026, an estimated $800K.
  • Mackenzie Financial first reported a position in Aclaris Therapeutics in Q1 2026 and held it in 1 quarter.
  • Mackenzie Financial's Aclaris Therapeutics position peaked at $800K in Q1 2026.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.